Literature DB >> 23152408

Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon.

Maria Arampatzidou1, André Schütte, Gunnar C Hansson, Paul Saftig, Klaudia Brix.   

Abstract

Cathepsin K has been shown to exhibit antimicrobial and anti-inflammatory activities in the mouse colon. To further elucidate its role, we used Ctsk-/- mice and demonstrated that the absence of cathepsin K was accompanied by elevated protein levels of related cysteine cathepsins (cathepsins B, L, and X) in the colon. In principle, such changes could result in altered subcellular localization; however, the trafficking of cysteine cathepsins was not affected in the colon of Ctsk-/- mice. However, cathepsin K deficiency affected the extracellular matrix constituents, as higher amounts of collagen IV and laminin were observed. Moreover, the localization pattern of the intercellular junction proteins E-cadherin and occludin was altered in the colon of Ctsk-/- mice, suggesting potential impairment of the barrier function. Thus, we used an ex vivo method for assessing the mucus layers and showed that the absence of cathepsin K had no influence on mucus organization and growth. The data of this study support the notion that cathepsin K contributes to intestinal homeostasis and tissue architecture, but the lack of cathepsin K activity is not expected to affect the mucus-depending barrier functions of the mouse colon. These results are important with regard to oral administration of cathepsin K inhibitors that are currently under investigation in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152408      PMCID: PMC4631841          DOI: 10.1515/hsz-2012-0204

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  50 in total

1.  The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions.

Authors:  Malin E V Johansson; Jessica M Holmén Larsson; Gunnar C Hansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-25       Impact factor: 11.205

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

3.  Release of endo-lysosomal cathepsins B, D, and L from IEC6 cells in a cell culture model mimicking intestinal manipulation.

Authors:  Kristina Mayer; Anna Vreemann; Hong Qu; Klaudia Brix
Journal:  Biol Chem       Date:  2009 May-Jun       Impact factor: 3.915

Review 4.  Osteoporosis: now and the future.

Authors:  Tilman D Rachner; Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet       Date:  2011-03-28       Impact factor: 79.321

5.  Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

Authors:  Izabela Podgorski
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

Review 6.  Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.

Authors:  E Michael Lewiecki
Journal:  IDrugs       Date:  2009-12

7.  Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools.

Authors:  Sylvie Desmarais; Frédéric Massé; M David Percival
Journal:  Biol Chem       Date:  2009-09       Impact factor: 3.915

8.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.

Authors:  P Saftig; E Hunziker; O Wehmeyer; S Jones; A Boyde; W Rommerskirch; J D Moritz; P Schu; K von Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits.

Authors:  Stephanie Dauth; Ruxandra F Sîrbulescu; Silvia Jordans; Maren Rehders; Linda Avena; Julia Oswald; Alexander Lerchl; Paul Saftig; Klaudia Brix
Journal:  BMC Neurosci       Date:  2011-07-27       Impact factor: 3.288

10.  Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions.

Authors:  Silvia Jordans; Sasa Jenko-Kokalj; Nicole M Kühl; Sofia Tedelind; Wolfgang Sendt; Dieter Brömme; Dusan Turk; Klaudia Brix
Journal:  BMC Biochem       Date:  2009-09-22       Impact factor: 4.059

View more
  5 in total

Review 1.  Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Authors:  Klaudia Brix; Joseph McInnes; Alaa Al-Hashimi; Maren Rehders; Tripti Tamhane; Mads H Haugen
Journal:  Protoplasma       Date:  2014-11-16       Impact factor: 3.356

2.  Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Vasileios C Kyttaris; Isaac E Stillman; Bruce Gelb; Peter Libby; George C Tsokos; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-01-16       Impact factor: 5.422

3.  Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.

Authors:  Yaongamphi Vashum; Riya Premsingh; Amuthavalli Kottaiswamy; Mathangi Soma; Abirami Padmanaban; Parkavi Kalaiselvan; Shila Samuel
Journal:  Mol Biol Rep       Date:  2020-12-08       Impact factor: 2.316

4.  Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma.

Authors:  Urška Verbovšek; Helena Motaln; Ana Rotter; Nadia A Atai; Kristina Gruden; Cornelis J F Van Noorden; Tamara T Lah
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 5.  Protease inhibition as new therapeutic strategy for GI diseases.

Authors:  Nathalie Vergnolle
Journal:  Gut       Date:  2016-04-12       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.